Concepedia

Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey

Mehmet Sinan Dal, Bahar Uncu Ulu, Ant Uzay, Olga Meltem Akay, Sevgi Kalayoğlu Beşışık, Mustafa Nuri Yenerel, Serhat Çelik, Leylagül Kaynar, Orhan Kemal Yücel, Burak Devecı,

Annals of Hematology · 2022 · 12 citations · 17 references

DOIFull text

Open access

Concepts

References

17

CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

Bertrand Coiffier, Éric Lepage, Josette Brière et al. · New England Journal of Medicine · 2002 · 5.6K citations · Full text

, , +9

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

Bruce D. Cheson, Richard I. Fisher, Sally F. Barrington et al. · Journal of Clinical Oncology · 2014 · 5.6K citations · Full text

, , +17

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study

Michael Crump, Sattva S. Neelapu, Umar Farooq et al. · Blood · 2017 · 1.7K citations · Full text

, , +10

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.

J. O. Armitage, Dennis D. Weisenburger · Journal of Clinical Oncology · 1998 · 1.3K citations

, , +14

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Laurie H. Sehn, Alex F. Herrera, Christopher R. Flowers et al. · Journal of Clinical Oncology · 2019 · 772 citations · Full text

, , +14